preserved ejection fraction

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction

This review synthesizes the pivotal EMPEROR-Preserved Trial results, highlighting empagliflozin’s efficacy in reducing heart failure outcomes in patients with preserved ejection fraction.

No Routine Benefit from Beta‑Blockers After Myocardial Infarction with Preserved Ejection Fraction: Individual‑Patient Meta‑analysis of Five Randomized Trials